Metabolic reprogramming in colorectal cancer: regulatory networks and therapy

Cell & Bioscience

Review

Lekun Fang¹  Shaomin Zou¹  Jieping Zhang¹ 

[1] Department of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-Sen University, 26 Yuanchun Er Heng Road, 510655, Guangzhou, Guangdong, China;Guangdong Institute of Gastroenterology, 510655, Guangzhou, China;

关键词: Colorectal cancer;    Metabolic reprogramming;    Metabolic enzymes;    Signal transduction;    Targeted therapy;   

DOI  :  10.1186/s13578-023-00977-w

 received in 2022-10-16, accepted in 2023-02-01,  发布年份 2023

来源: Springer

【 摘 要 】

With high prevalence and mortality, together with metabolic reprogramming, colorectal cancer is a leading cause of cancer-related death. Metabolic reprogramming gives tumors the capacity for long-term cell proliferation, making it a distinguishing feature of cancer. Energy and intermediate metabolites produced by metabolic reprogramming fuel the rapid growth of cancer cells. Aberrant metabolic enzyme-mediated tumor metabolism is regulated at multiple levels. Notably, tumor metabolism is affected by nutrient levels, cell interactions, and transcriptional and posttranscriptional regulation. Understanding the crosstalk between metabolic enzymes and colorectal carcinogenesis factors is particularly important to advance research for targeted cancer therapy strategies via the investigation into the aberrant regulation of metabolic pathways. Hence, the abnormal roles and regulation of metabolic enzymes in recent years are reviewed in this paper, which provides an overview of targeted inhibitors for targeting metabolic enzymes in colorectal cancer that have been identified through tumor research or clinical trials.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 5

Fig. 5

42004_2023_830_Article_IEq12.gif

Fig. 1